-
Many elderly Americans still are being prescribed potentially inappropriate medications, according to a study published in the Aug. 9/23 issue of the Archives of Internal Medicine.
-
Some physicians advocate early, aggressive therapy to help reduce low-density lipoprotein (LDL) cholesterol levels. One new study, however, indicates that patients treated with high-dose simvastatin (Zocor) did not show a significant reduction in the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, readmission for acute coronary syndrome (ACS), and stroke.
-
The National Cholesterol Education Program, a product of a collaboration of the National Heart, Lung, and Blood Institutes, the American College of Cardiology, and the American Heart Association, has updated its clinical practice guideline on cholesterol management.
-
-
The hundreds of presentations at this meeting provided encouraging evidence that existing Alzheimers therapies may have greater benefits than first realized, and that a new generation of potential disease-modifying therapies for AD may be on the way.
-
It seems prudent to strongly consider use of melatonin in our cognitively delayed patients with disordered sleep, but to monitor those with epilepsy very closely for exacerbation, and withdraw the drug.
-
These studies provide additional data about the higher risk of relapse, and the greater potential for progression of disability following childbirth.
-
Absence of evidence-based medicine is both humbling, as well as a reminder of how substantial a role the art and oral tradition of medicine plays in the care of neurologic patients.
-
Methylprednisolone significantly improves the recovery of peripheral vestibular function in patients with vestibular neuritis, whereas valacyclovir does not.
-
